Potential effects of liver dysfunction at the time of diagnosis in patients with acute myeloid leukemia

Yilmaz,Fatma; Saygili,Derya Insal; Saglam,Bugra; Aras,Merih Reis; Afacan Ozturk,Hacer Berna; Gunes,Ahmet Kursad; Albayrak,Murat

doi:10.3892/etm.2025.12795

Potential effects of liver dysfunction at the time of diagnosis in patients with acute myeloid leukemia

Authors:
- Fatma Yilmaz
- Derya Insal Saygili
- Bugra Saglam
- Merih Reis Aras
- Hacer Berna Afacan Ozturk
- Ahmet Kursad Gunes
- Murat Albayrak
View Affiliations

Affiliations: Department of Hematology, Etlik City Hospital, Ankara 06170, Turkey, Faculty of Medicine, Department of Internal Medicine, Harran Univercity, Şanlıurfa 63290, Turkey, Department of Hematology, Medical Point Hospital, Gaziantep 27584, Turkey
Published online on: January 8, 2025 https://doi.org/10.3892/etm.2025.12795
Article Number: 45

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Whilst severe liver dysfunction is rarely encountered at the time of diagnosis for patients with acute myeloid leukemia (AML), mild elevations aminotransferase (<5 times the upper limit of normal) may be more frequently seen. Liver dysfunction at the time of diagnosis of AML is a parameter that requires investigation and can assist the clinicians in predicting prognosis. The aim of the present study was to investigate liver dysfunction at the time of diagnosis using the assoicated parameters in patients with AML. The present retrospective study included 90 patients diagnosed with AML who were hospitalised in the Hematology Clinic of Dışkapı Yıldırım Beyazıt Training and Research Hospital (Ankara, Turkey). The demographic characteristics of the patients were recorded together with hemogram results, anemia parameters, measurable residual disease positivity (MRD) and risk category, the presence of hepatosplenomegaly, infection, neutrophil recovery time (NRT), platelet recovery time (PRT) and liver dysfunction. The patients were analyzed in two groups following sorting into the liver dysfunction (n=45) and normal liver function test group (n=45). In the analysis of independent quantitative data (age, white blood cell count, hemoglobin, platelet, international normalized ratio, albumin, B12 vitamin, NRT, PRT) the Mann Whitney U‑test was used. Independent qualitative data (sex, hepatomegaly, splenomegaly, MRD, risk category, infection) were analyzed using the χ2 test or the Fischer test. The effect level was investigated using univariate and multivariate logistic regression. A receiver operating characteristic curve was applied to determine the effect level and cut‑off values. In the group with liver dysfunction, NRT, PRT, MRD positivity, risk category and the presence of infection were found to be statistically significantly higher. These findings suggest that during the first evaluation of patients diagnosed with AML, liver function tests are simple, rapid and necessary. The results obtained in the present study showed that liver dysfunction at diagnosis can be associated with the high‑risk group, in addition to more frequent infection, poorer prognosis and mortality.

View Figures

View References

1	Chennamadhavuni A, Lyengar V, Mukkamalla S and Shimanovsky A: Leukemia.[Updated 2023 Jan 17]. StatPearls Publishing, Treasure Island, FL, 2023.
2	Chennamadhavuni A, Lyengar V and Shimanovsky A: Leukemia. StatPearls. StatPearls Publishing, Treasure Island, FL, USA, 2022.
3	Stubbins RJ, Francis A, Kuchenbauer F and Sanford D: Management of acute myeloid leukemia: A review for general practitioners in oncology. Curr Oncol. 29:6245–6259. 2022.PubMed/NCBI View Article : Google Scholar
4	Künz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D and Steiner N: Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers (Basel). 14(4290)2022.PubMed/NCBI View Article : Google Scholar
5	Bruguera M and Miquel R: The Effect of Haematological and Lymphatic Diseases on the Liver. In: Textbook of Hepatology: From basic science to clinical practice. Rodés J, Benhamou JP, Blei AT, Reichen J, Rizzetto M (eds). Wiley, Hoboken, NJ, 1662-1670, 2007.
6	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017.PubMed/NCBI View Article : Google Scholar
7	Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, et al: Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 140:1345–1377. 2022.PubMed/NCBI View Article : Google Scholar
8	Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, Brandt M, Wang S, Konoplev S, Wang X, et al: Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 123:426–435. 2017.PubMed/NCBI View Article : Google Scholar
9	San Miguel JF, Vidriales MB, López-Berges C, Dıaz-Mediavilla J, Gutiérrez N, Canizo C, Ramos F, Calmuntia MJ, Pérez JJ, González M and Orfao A: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood. 98:1746–1751. 2001.PubMed/NCBI View Article : Google Scholar
10	Shan S, Zhao XY and Jia JD: Hepatic manifestations of hematological diseases. Zhonghua Gan Zang Bing Za Zhi. 30:347–351. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese).
11	Vakiti A and Mewawalla P: Acute myeloid leukemia, 2018.
12	Park HS: What is new in acute myeloid leukemia classification? Blood Res. 59(15)2024.PubMed/NCBI View Article : Google Scholar
13	Shallis RM, Wang R, Davidoff A, Ma X and Zeidan AM: Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 36:70–87. 2019.PubMed/NCBI View Article : Google Scholar
14	Pulumati A, Pulumati A, Dwarakanath BS, Verma A and Papineni RV: Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep (Hoboken). 6(e1764)2023.PubMed/NCBI View Article : Google Scholar
15	Medvinsky A, Rybtsov S and Taoudi S: Embryonic origin of the adult hematopoietic system: Advances and questions. Development. 138:1017–1031. 2011.PubMed/NCBI View Article : Google Scholar
16	Ebert EC and Hagspiel KD: Gastrointestinal manifestations of leukemia. J Gastroenterol Hepatol. 27:458–463. 2012.PubMed/NCBI View Article : Google Scholar
17	Edwards L and Wanless IR: Mechanisms of liver involvement in systemic disease. Best Pract Res Clin Gastroenterol. 27:471–483. 2013.PubMed/NCBI View Article : Google Scholar
18	Gu RL, Xiang M, Suo J and Yuan J: Acute lymphoblastic leukemia in an adolescent presenting with acute hepatic failure: A case report. Mol Clin Oncol. 11:135–138. 2019.PubMed/NCBI View Article : Google Scholar
19	Walsh LR, Yuan C, Boothe JT, Conway HE, Mindiola-Romero AE, Barrett-Campbell OO, Yerrabothala S and Lansigan F: Acute myeloid leukemia with hepatic infiltration presenting as obstructive jaundice. Leuk Res Rep. 15(100251)2021.PubMed/NCBI View Article : Google Scholar
20	Kreiniz N, Katz OB, Polliack A and Tadmor T: The clinical spectrum of hepatic manifestations in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 17:863–869. 2017.PubMed/NCBI View Article : Google Scholar
21	Segal I, Rassekh SR, Bond MC, Senger C and Schreiber RA: Abnormal liver transaminases and conjugated hyperbilirubinemia at presentation of acute lymphoblastic leukemia. Pediatr Blood Cancer. 55:434–439. 2010.PubMed/NCBI View Article : Google Scholar
22	Sandart A, Harila-Saari A, Arnell H, Fischler B and Vakkila J: Pattern and prevalence of liver involvement in pediatric acute lymphoblastic and myeloid leukemia at diagnosis. J Pediatr Gastroenterol Nutr. 73:630–635. 2021.PubMed/NCBI View Article : Google Scholar
23	Choi JH, Shukla M and Abdul-Hay M: Acute myeloid leukemia treatment in the elderly: A comprehensive review of the present and future. Acta Haematol. 146:431–457. 2023.PubMed/NCBI View Article : Google Scholar
24	Tazi Y, Arango-Ossa JE, Zhou Y, Bernard E, Thomas I, Gilkes A, Freeman S, Pradat Y, Johnson SJ, Hills R, et al: Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 13(4622)2022.PubMed/NCBI View Article : Google Scholar
25	Hourigan C, Gale R, Gormley N, Ossenkoppele G and Walter R: Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 31:1482–1490. 2017.PubMed/NCBI View Article : Google Scholar
26	Lustberg MB: Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 10(825)2012.PubMed/NCBI
27	Gao A, Zhang L and Zhong D: Chemotherapy-induced thrombocytopenia: Literature review. Discov Oncol. 14(10)2023.PubMed/NCBI View Article : Google Scholar
28	Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, Ito S, Tachibana T, Hagihara M, Matsumoto K, et al: Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia. Leuk Lymphoma. 58:104–109. 2017.PubMed/NCBI View Article : Google Scholar
29	Løhmann DJ, Asdahl PH, Abrahamsson J, Ha SY, Jónsson ÓG, Kaspers GJL, Koskenvuo M, Lausen B, De Moerloose B, Palle J, et al: Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. Pediatr Blood Cancer. 65(e27231)2018.PubMed/NCBI View Article : Google Scholar
30	Van de Louw A, Twomey K, Habecker N and Rakszawski K: Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: A single-center retrospective cohort study. Ann Hematol. 100:229–237. 2021.PubMed/NCBI View Article : Google Scholar